Order Article Reprints

Yang Z, Suda G, Maehara O, Ohara M, Yoshida S, Hosoda S, Kimura M, Kubo A, Tokuchi Y, Fu Q, et al. Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers. 2022; 14(1):232. https://doi.org/10.3390/cancers14010232

Yang, Zijian, Goki Suda, Osamu Maehara, Masatsugu Ohara, Sonoe Yoshida, Shunichi Hosoda, Megumi Kimura, Akinori Kubo, Yoshimasa Tokuchi, Qingjie Fu, and et al. 2022. "Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma" Cancers 14, no. 1: 232. https://doi.org/10.3390/cancers14010232

Yang, Z., Suda, G., Maehara, O., Ohara, M., Yoshida, S., Hosoda, S., Kimura, M., Kubo, A., Tokuchi, Y., Fu, Q., Yamada, R., Kitagataya, T., Suzuki, K., Kawagishi, N., Nakai, M., Sho, T., Natsuizaka, M., Morikawa, K., Ogawa, K., ... Sakamoto, N. (2022). Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 14(1), 232. https://doi.org/10.3390/cancers14010232